Anti-Claudin 18.2 CAR-T cell therapy - First Affiliated Hospital Xi'an Jiaotong University
Alternative Names: Anti-Claudin 18.2 chimeric antigen receptor T cell therapy - First Affiliated Hospital Xi'an Jiaotong University; LCAR-C182A/LCAR-C182B/LCAR-C182C cellsLatest Information Update: 28 May 2022
At a glance
- Originator First Affiliated Hospital-Xi'an Jiaotong University
- Developer First Affiliated Hospital-Xi'an Jiaotong University; Nanjing Legend Biotech
- Class CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Gastric cancer; Pancreatic cancer
Most Recent Events
- 28 May 2022 No recent reports of development identified for phase-I development in Gastric-cancer(Inoperable/Unresectable, Late-stage disease, Refractory metastatic disease, Second-line therapy or greater) in China (IV, Infusion)
- 28 May 2022 No recent reports of development identified for phase-I development in Pancreatic-cancer(Inoperable/Unresectable, Late-stage disease, Refractory metastatic disease, Second-line therapy or greater) in China (IV, Infusion)
- 02 Jul 2020 First Affiliated Hospital Xi'an Jiaotong University and Nanjing Legend Biotech terminates phase I trial in Gastric cancer and pancreatic cancer due to the preliminary data, progress of this study and the adjustment of the pipeline and strategy in China (NCT03890198)